Bone turnover markers: Understanding their value in clinical trials and clinical practice

Osteoporosis International

Volumn 20, Issue 6, 2009, Pages 843-851

  Civitelli, R ^a   Armamento Villareal, R ^a   Napoli, N ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b Campus Bio Medico di Roma ^*  (Italy)

Author keywords

Bone mineral density; Bone remodeling; Bone turnover markers; Fracture risk; Osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; DENOSUMAB; DEOXYPYRIDINOLINE; ESTROGEN; IBANDRONIC ACID; OSTEOCALCIN; PROCOLLAGEN TYPE 1 CARBOXY TERMINAL PROPEPTIDE; PYRIDINOLINE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; STRONTIUM RANELATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DENSITY; BONE MASS; BONE TURNOVER; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VERTEBRA FRACTURE;

ABSORPTIOMETRY, PHOTON; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CLINICAL TRIALS AS TOPIC; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 67349103852     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0838-9     Document Type: Review

References (92)

1. World Health Organization 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843 1 129
2. ACOG practice bulletin 2004 Clinical management guidelines for obstetrician-gynecologists Obstet Gynecol 103 203 216
3. JA Kanis 2002 Diagnosis of osteoporosis and assessment of fracture risk Lancet 359 1929 1936
4. DB Burr 2003 Introduction-bone turnover and fracture risk J Musculoskelet Neuronal Interact 3 408 409
5. ES Siris YT Chen TA Abbott 2004 Bone mineral density thresholds for pharmacological intervention to prevent fractures Arch Intern Med 164 1108 1112
6. JA Kanis O Johnell A Oden 2008 FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385 397
7. P Garnero E Sornay-Rendu MC Chapuy 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis J Bone Miner Res 11 337 349
8. BL Riggs LJ Melton 3rd 2002 Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density J Bone Miner Res 17 11 4
9. RP Heaney 2003 Remodeling and skeletal fragility Osteoporos Int 14 suppl 5 S12 S15
10. SR Cummings DB Karpf F Harris 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281 289
11. A Claudon P Vergnaud C Valverde 2008 New automated multiplex assay for bone turnover markers in osteoporosis Clin Chem 54 1554 1563
12. P Garnero P Vergnaud N Hoyle 2008 Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis Clin Chem 54 188 196
13. H Schmidt-Gayk E Spanuth J Kötting 2004 Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study) Clin Chem Lab Med 42 90 95
14. S Cremers P Garnero 2006 Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls Drugs 66 2031 2058
15. Y Abe H Ishikawa A Fukao 2008 Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women Tohoku J Exp Med 214 51 59
16. JD Clemens MV Herrick FR Singer 1997 Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption Clin Chem 43 2058 2063
17. DA Hanson MA Weis AM Bollen 1992 A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine J Bone Miner Res 7 1251 1258
18. Risteli J, Risteli L (1999) Products of bone collagen metabolism. In: Seibel M, Robins S, Bilezikian J (eds) Dynamics of bone and cartilage metabolism. Academic, San Diego, California, pp 275-288
19. J Risteli I Elomaa S Niemi 1993 Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation Clin Chem 39 635 640
20. P Garnero O Borel PD Delmas 2001 Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis Clin Chem 47 694 702
21. C Fledelius AH Johnsen PA Cloos 1997 Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region J Biol Chem 272 9755 9763
22. P Garnero E Gineyts AV Schaffer 1998 Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease Arthritis Rheum 41 354 360
23. P Garnero P Cloos E Sornay-Rendu 2002 Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study J Bone Miner Res 17 826 833
24. AK Srivastava EL Vliet EM Lewiecki 2005 Clinical use of serum and urine bone markers in the management of osteoporosis Curr Med Res Opin 21 1015 1026
25. Z Gunja-Smith RJ Boucek 1981 Collagen cross-linking compounds in human urine Biochem J 197 759 762
26. MJ Seibel 2005 Biochemical markers of bone turnover: part I: biochemistry and variability Clin Biochem Rev 26 97 122
27. ME Kraenzlin CA Kraenzlin C Meier 2008 Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases Clin Chem 54 1546 1553
28. JM Halleen SL Alatalo AJ Janckila 2001 Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption Clin Chem 47 597 600
29. R Hannon A Blumsohn K Naylor 1998 Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability J Bone Miner Res 13 1124 1133
30. KM Prestwood CC Pilbeam JA Burleson 1994 The short-term effects of conjugated estrogen on bone turnover in older women J Clin Endocrinol Metab 79 366 371
31. D Eyre 1992 New biomarkers of bone resorption J Clin Endocrinol Metab 74 470A 470C
32. PD Delmas 1990 Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease Endocrinol Metab Clin North Am 19 1 18
33. L Moro RS Pozzi Mucelli 1988 Urinary beta-1-galactosyl-0-hydroxylysine (GH) as a marker of collagen turnover of bone Calcif Tissue Int 42 87 90
34. Price PA (1987) Vitamin K-dependent proteins. In: Cohn DV (ed) Calcium regulation and bone metabolism basic and clinical aspects. Amsterdam, Elsevier Science, The Netherlands, pp 419-425
35. Dickson IR (1993) Bone. In: Royce PM, Steinmann B (eds) Connective tissue and its heritable disorders. Wiley-Liss, New York, pp 249-285
36. PA Price 1985 Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function Vitam Horm 42 65 108
37. BL Riggs KS Tsai KG Mann 1986 Effect of acute increases in bone matrix degradation on circulating levels of bone-Gla protein J Bone Miner Res 1 539 542
38. P Garnero M Grimaux P Seguin 1994 Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro J Bone Miner Res 9 255 264
39. AK Taylor S Linkhart S Mohan 1990 Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay J Clin Endocrinol Metab 7 467 472
40. MG Low 1987 Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors Biochem J 244 1 13
41. H Harris 1990 The human alkaline phosphatases: what we know and what we don't know Clin Chim Acta 186 133 150
42. S Green CL Anstiss WH Fishman 1971 Automated differential isoenzyme analysis. II. The fractionation of serum alkaline phosphatases into "liver", "intestinal" and "other" components Enzymologia 41 9 26
43. JR Farley CH Chesnut 3rd DJ Baylink 1981 Improved method for quantitative determination in serum of alkaline phosphatase of skeletal origin Clin Chem 27 2002 2007
44. SH Liu RS Yang R al-Shaikh 1995 Collagen in tendon, ligament, and bone healing. A current review Clin Orthop Relat Res 318 265 278
45. Woo SLY, An KN, Arnoczky SP et al (1994) Anatomy, biology and biomechanics of tendon, ligament and meniscus. In: Simon SR (ed) Orthopaedic basic science. American Academy of Orthopaedic Surgeons, Chicago, pp 45-88
46. B Smedsrod J Melkko L Risteli 1990 Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells Biochem J 271 345 350
47. D Lüftner D Jozereau S Schildhauer 2005 PINP as serum marker of metastatic spread to the bone in breast cancer patients Anticancer Res 25 1491 1499
48. J Toivonen R Tähtelä K Laitinen 1998 Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy Eur J Endocrinol 138 667 673
49. PM Crofton JC Wade MR Taylor 1997 Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren Clin Chem 43 1577 1581
50. P Garnero E Sornay-Rendu B Claustrat 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY Study J Bone Miner Res 15 1526 1536
51. P Garnero E Hausherr MC Chapuy 1996 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study J Bone Miner Res 11 1531 1538
52. PL van Daele MJ Seibel H Burger 1996 Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam Study BMJ 312 482 483
53. PD Ross BC Kress RE Parson 2000 Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study Osteoporos Int 11 76 82
54. DC Bauer PM Sklarin KL Stone 1999 Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures J Bone Miner Res 14 1404 1410
55. R Eastell I Barton RA Hannon 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 1051 1056
56. R Eastell RA Hannon P Garnero 2007 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis J Bone Miner Res 22 1656 1660
57. JY Reginster S Adami P Lakatos 2006 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE Study Ann Rheum Dis 65 654 661
58. R Recker JA Stakkestad CH Chesnut 3rd 2004 Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis Bone 34 890 899
59. DC Bauer P Garnero MC Hochberg for the Fracture Intervention Research Group 2006 Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial J Bone Miner Res 21 292 299
60. DM Black PD Delmas R Eastell 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822
61. RS Weinstein AM Parfitt R Marcus 2003 Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women Osteoporos Int 14 814 822
62. HG Bone MA Bolognese CK Yuen 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women J Clin Endocrinol Metab 93 2149 2157
63. Anastasilakis AD, Goulis DG, Polyzos SA, et al (2009) No difference between strontium ranelate and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. Clin Endocrinol (Oxf). doi: 10.1111/j.1365-2265. 2008.03342.x
64. MC Hochberg S Greenspan RD Wasnich 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J Clin Endocrinol Metab 87 1586 1592
65. L Raisz JA Smith M Trahiotis 2000 Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover Osteoporos Int 11 615 620
66. A Braga de Castro Machado R Hannon R Eastell 1999 Monitoring alendronate therapy for osteoporosis J Bone Miner Res 14 602 608
67. H Aoshima K Kushida M Takahashi 1998 Circadian variation of urinary type I collagen crosslinked C-telopeptide and free and peptide-bound forms of pyridinium crosslinks Bone 22 73 78
68. D Borderie C Roux B Toussaint 2001 Variability in urinary excretion of bone resorption markers: limitations of a single determination in clinical practice Clin Biochem 34 571 577
69. HS Ju S Leung B Brown 1997 Comparison of analytical performance and biological variability of three bone resorption assays Clin Chem 43 1570 1576
70. C Gluer 1999 Monitoring skeletal changes by radiologic techniques J Bone Miner Res 14 1952 1962
71. JA Shepherd SL Morgan Y Lu 2008 Comparing BMD results between two similar DXA systems using the generalized least significant changes J Clin Densitom 11 237 242
72. DC Bauer P Garnero JP Bilezikian 2006 Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis J Clin Endocrinol Metab 91 1370 1375
73. CL Raehl CA Bond TJ Woods 2006 Screening tests for intended medication adherence among the elderly Ann Pharmacother 40 888 893
74. CA [tmp] McHorney JT Schousboe RR Cline 2007 The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 23 3137 3152
75. JJ Caro KJ Ishak KF Huybrechts 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003 1008
76. JA Cramer MM Amonkar A Hebborn 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460
77. DH Solomon J Avorn JN Katz 2005 Compliance with osteoporosis medications Arch Intern Med 165 2414 2419
78. A Cooper J Drake E Brankin 2006 Treatment persistence with once monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST Study Int J Clin Pract 60 896 905
79. MJ Seibel 2006 Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis Clin Biochem Rev 27 123 138
80. RG Russell MJ Rogers 1999 Bisphosphonates: from the laboratory to the clinic and back again Bone 25 97 106
81. JA Clowes NF Peel R Eastell 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J Clin Endocrinol Metab 89 1117 1123
82. PD Delmas B Vrijens C Roux 2003 A reinforcement message based on bone turnover markers response influences long-term persistence with risedronate in osteoporosis: the IMPACT Study J Bone Miner Res 18 suppl 2 S374
83. R Civitelli S Gonnelli F Zacchei 1988 Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment J Clin Invest 82 1268 1274
84. CH Chesnut III NH Bell GS Clark 1997 Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density Am J Med 102 29 37
85. D Uebelhart A Schlemmer JS Johansen 1991 Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links J Clin Endocrinol Metab 72 367 373
86. B Ettinger DM Black BH Mitlak 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637 645
87. ST Harris NB Watts HK Genant 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352
88. MB Schaffler K Choi C Milgrom 1995 Aging and matrix microdamage accumulation in human compact bone Bone 17 521 525
89. T Mashiba T Hirano CH Turner 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib J Bone Miner Res 15 613 620
90. ML Bouxsein 2003 Bone quality: where do we go from here? Osteoporos Int 14 suppl 5 118 127
91. M Visekruna D Wilson FE [tmp] McKiernan 2008 Severely suppressed bone turnover and atypical skeletal fragility J Clin Endocrinol Metab 93 2948 2952
92. AS Neviaser JM Lane BA Lenart 2008 Low-energy femoral shaft fractures associated with alendronate use J Orthop Trauma 22 346 350